Although growth stock picks can be highly volatile, they can make good long-term investments. They may be well-known stars or quiet gems, but they do share one common attribute—they are growing at a higher-than-average rate within their industry, or within the market as a whole, and could keep growing for years or decades.
And keep in mind that we focus on growth stocks, which have a good long-term history and favourable prospects. We downplay momentum stocks that tend to attract many investors simply because they are moving faster than the market averages, but are liable to fall sharply when their momentum fades.
There’s room for growth stock investing in your portfolio, but make sure you follow our TSI Network three-part Successful Investor strategy for your overall portfolio:
- Invest mainly in well-established companies;
- Spread your money out across most if not all of the five main economic sectors (Manufacturing & Industry; Resources & Commodities; Consumer; Finance; Utilities);
- Downplay or avoid stocks in the broker/media limelight.
Make better stock picks when you read this FREE Special Report, Canadian Growth Stocks: WestJet Stock, RioCan Stock and More.
The stock has gained 60% in the past year. However, that’s mainly due to its rising distributions, which could slow this year.
Cedar Fair is still a hold....
The company plans to launch 15 new vehicles in China by 2015. It also aims to double its production capacity in China, to 1.2 million vehicles, by 2015.
Ford is a buy.
...
In response to the lower prices, the company has already closed about 13% of its smelting capacity. It is now thinking about lowering its production by a further 11%. This should help it reach its goal of cutting its operating costs by around 10% by 2015.
Alcoa is a buy.
...
The company continues to benefit from its move to charge users for access to its newspapers’ websites: revenue from its Internet operations (which supply 15% of the total) rose 3.9%. It now has 50,000 digital subscribers and feels this will rise to 300,000 by 2014. However, weaker demand for print advertising cut revenue at Gannett’s newspaper division (69% of revenue) by 0.3%. Revenue from its 23 TV stations (16%) rose 8.7% due to higher retransmission fees from cable and satellite TV operators.
Gannett is a buy.
...
This spending should continue to fall in future years, because many of the projects that BHP is developing will start up in 2015.
BHP Billiton is a buy....
Meanwhile, Archer Daniels earned $269 million, or $0.41 a share, in the three months ended March 31, 2013. That’s down 32.6% from $399 million, or $0.60 a share, a year earlier. If you exclude writedowns and other unusual items, per-share earnings fell 38.5%, to $0.48 from $0.78.
Last year’s drought in the U.S. increased the prices that Archer Daniels’ food-processing operations paid for soybeans and other crops. That was the main reason for the lower earnings. However, revenue rose 2.7%, to $21.7 billion from $21.2 billion, as falling ethanol inventories helped increase prices.
...
Monsanto gets over 70% of its revenue by selling genetically modified seeds, so allowing farmers to replant these seeds would have significantly hurt the company’s prospects. The remaining 30% comes from pest- and weed-control products.
Meanwhile, Monsanto earned $1.5 billion, or $2.74 a share, in the three months ended February 28, 2013. That’s up 22.5% from $1.2 billion, or $2.24 a share, a year earlier. If you disregard unusual items, mainly costs to clean up contamination at a chemical plant in West Virginia, earnings per share would have risen 19.7%, to $2.73 from $2.28. Sales rose 15.2%, to $5.5 billion from $4.7 billion. That’s mainly due to strong sales of its corn seeds in Brazil.
...
As well, more people are using their smartphone’s built-in camera to take pictures. That’s hurting sales of Canon’s low-priced compact cameras.
Canon is still a hold....
Bard recently agreed to pay $50.5 million to settle allegations that from 1998 to 2006 the company offered hospitals free equipment and other benefits if they used its cancer-treatment products.
If you exclude these costs, Bard’s earnings fell 13.5% in the first quarter of 2013, to $120.7 million from $139.5 million a year earlier. Earnings per share fell 10.6%, to $1.44 from $1.61, on fewer shares outstanding. However, sales rose 1.4%, to $740.3 million from $730.0 million. Bard spent 8.0% of its sales on research in the quarter, up from 6.6% a year earlier.
...